Non-target progression--the fine line between objectivity and subjectivity

Eur J Cancer. 2014 Dec;50(18):3271-2. doi: 10.1016/j.ejca.2014.08.021. Epub 2014 Oct 18.

Authors

Stephanie Lheureux¹, Michelle K Wilson¹, Martin O'Malley², Mehrdad Sinaei², Amit M Oza³

Affiliations

¹ Division of Medical Oncology and Haematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Department of Medical Imaging, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
³ Division of Medical Oncology and Haematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: amit.oza@uhn.ca.

PMID: 25450948
DOI: 10.1016/j.ejca.2014.08.021

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms / therapy*
Colorectal Neoplasms / therapy*
Databases, Factual*
Female
Humans
Lung Neoplasms / therapy*
Male
Models, Statistical*
Tumor Burden*